Therapeutic Targeting of microRNAs in Cancer: Future Perspectives
Authors:
- 26 August 2015
- journal article
- review article
- Published by Wiley in Drug Development Research
- Vol. 76 (7) , 382-388
Abstract
Preclinical Research The discovery of microRNAs (miRNAs) and their link with cancer has opened a new era in cancer therapeutics. Approximately, 18 − 24 nucleotides long, miRNAs can up‐regulate or down‐regulate gene expression in many cancer types and are respectively categorized as oncogenes (oncomirs) or tumor suppressors. Expression profiles of miRNAs with biomarker potential can be used for the classification, diagnosis, therapeutic treatment, and prognosis of different cancer types. miRNA mimics and miRNA antagonists are the two main approaches to miRNA‐based cancer therapies that respectively inhibit oncomirs or restore the expression of tumor suppressive miRNAs. This review serves to provide some general insight into miRNA biogenesis, cancer related miRNAs, and miRNA therapeutics. Drug Dev Res 76 : 382–388, 2015.Keywords
This publication has 95 references indexed in Scilit:
- MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive reviewEMBO Molecular Medicine, 2012
- Molecular Mechanisms of RNA-Triggered Gene Silencing MachineriesAccounts of Chemical Research, 2012
- Systemic Delivery of Tumor Suppressor microRNA Mimics Using a Neutral Lipid Emulsion Inhibits Lung Tumors in MiceMolecular Therapy, 2011
- Small‐Molecule Inhibitors of MicroRNA miR‐21 FunctionAngewandte Chemie International Edition, 2008
- miRiad Roles for the miR-17-92 Cluster in Development and DiseaseCell, 2008
- Silencing of microRNAs in vivo with ‘antagomirs’Nature, 2005
- TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencingNature, 2005
- MicroRNA expression profiles classify human cancersNature, 2005
- c-Myc-regulated microRNAs modulate E2F1 expressionNature, 2005
- Processing of primary microRNAs by the Microprocessor complexNature, 2004